26
Aug
2021

Pfizer / BioNTech Vaccine Approved, Lilly Works With Lycia, & We Wait for J&J

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Eikon IPO on Deck, Biomarin Borrows Big, & Halozyme Rolls with the Surf
GSK Scoops Up RAPT, Genentech Bets on NC, & Relief for American Science
Novo Rolls Out Wegovy Pill, Lilly Acquires Ventyx NLRP3, and Aktis Breaks IPO Ice
Lilly Rolling in Obesity, Kymera Challenges Dupixent & Takeda Nails Tyk2